Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT06863233
Official study title

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Study summary

The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedZirconium Zr 89 crefmirlimab berdoxam and PET/CT Scan

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 26, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Phase 1
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Drug: Zirconium Zr 89 crefmirlimab berdoxam; Diagnostic Test: PET/CT Scan
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patient must be 18 years of age or older at the time of signing the informed consent.
  • Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer
  • Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
  • Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product.
  • Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Patient or legally authorized representative provided written authorization for use and disclosure of protected health information.
Reasons someone may not be able to joinExclusion criteria
  • Pregnant or breastfeeding women
  • Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memorial Sloan Kettering at Basking Ridge (Consent Only)Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Consent Only)Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Consent Only)Montvale, New Jersey
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)Commack, New York
  • Memorial Sloan Kettering Westchester (Consent only)Harrison, New York
  • Memorial Sloan Kettering Cancer Center (All protocol activities)New York, New York
  • Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)Uniondale, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 26, 2026. Always confirm current availability with the study team.

View original record ↗